ARDD 2026 will be held in Boston from October 1 to 3, where researchers, companies, and regulators will discuss biomarkers of biological aging, clinical endpoints for healthspan, and the development of interventions targeting aging. FDA has proposed two potential regulatory pathways: demonstrating benefits across multiple age-related diseases, or establishing broader aging indications using functional measures such as cognition, frailty, and vision. It also plans to develop new trial guidance in early FY2027.
Source:Heales EN · Read original article
Leave a Reply